Comparison of the therapeutic effects of alendronate and zoledronic acid in postmenopausal women with osteoporosis
Wen-jie WANG,Wen-zhen FU,Jin-wei HE,Chun WANG,Zhen-lin ZHANG
DOI: https://doi.org/10.3969/j.issn.1674-2591.2017.05.003
2017-01-01
Abstract:Objective To retrospective investigation and analysis the therapeutic effects of one year weekly oral alendronate ( ALN) or once-yearly i. v. infusion of zoledronic acid ( ZOL) treatment in postmenopausal Chinese women with osteoporosis. Methods Eighty women with osteoporosis receiving ALN (70 mg, one time a week, at least 1 year) and 80 women with osteoporosis or osteopenia receiving ZOL ( 5 mg, one time a year, at least 1 year) from Dec 2014 to Jan 2016 were chosen as subjects. Simultaneously, they were treated with calcium 600 mg qd and vitamin D 125 IU qd for 12 months. The bone densitometry at lumbar spine1-4, left femoral neck, total hip bone and bone turnover markerβ-CTX level were measured at baseline and after 1 year of treatment respectively. Results The average age of participants in ALN group and ZOL group were (66. 48±8. 39) years and (65. 11±7. 69) years. After 12 months of treatment, change in BMD in ALN group of L1-4, the femoral neck, the total hip was (5. 46±4. 42)%, (2. 81%±3. 83)%, (2. 72±2. 76)%, respectively (P<0. 001). And change in BMD in ZOL group of L1-4, the femoral neck, the total hip was (6. 66%± 6. 37)%, (1. 97±3. 13)%, (2. 20±3. 63)%, respectively (P<0. 001). There were no significant differences in the im-provement of BMD and bone turnover markers between two groups (P=0. 216, P=0. 132, P=0. 312, P=0. 066). Conclusions Treatment with ALN or ZOL can significantly increased the BMD at lumbar spine, femoral neck and total hip. There are no significant differences in the therapeutic effects between ALN and ZOL treatment.